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Almost all cervical cancers are associated with human papillomavirus (HPV); however, the majority of women infected with this
virus do not develop cervical cancer. Therefore, new markers are needed for reliable screening of cervical cancer, especially in
relation to HPV infection. We aimed to identify potential microRNAs that may serve as diagnostic markers for cervical cancer
development in high-risk HPV-positive patients. We evaluated the microRNA expression profiles in 12 cervical tissues using the
hybridization method and verified them by quantitative polymerase chain reaction (qPCR). Finally, we evaluated the effects of
HPV16 oncoproteins on the expression of selectedmicroRNAs using cervical cancer cells (CaSki and SiHa) and RNA interference.
With the hybridization method, eight microRNAs (miR-9-5p, miR-136-5p, miR-148a-3p, miR-190a-5p, miR-199b-5p, miR-382-5p,
miR-597-5p, and miR-655-3p) were found to be expressed differently in the HPV16-positive cervical cancer group and HPV16-
positive normal group (fold change ≥ 2). The results of qPCR showed that miR-148a-3p, miR-190a-5p, miR-199b-5p, and miR-655-
3p levels significantly decreased in the cancer group compared with the normal group. Upon silencing of HPV16 E5 and E6/E7,
miR-148a-3p levels increased in both cell lines. Silencing of E6/E7 in SiHa cells led to the increase inmiR-199b-5p andmiR-190a-5p
levels.Three HPV16 oncoproteins (E5, E6, and E7) downregulate miR-148a-3p, while E6/E7 inhibit miR-199b-5p and miR-190a-5p
expression in cervical carcinoma. The three microRNAs, miR-148a-3p, miR-199b-5p, and miR-190a-5p, may be novel diagnostic
biomarkers for cervical cancer development in high-risk HPV-positive patients.
1. Introduction
The interaction between viral and host factors is important
in cervical carcinogenesis because it triggers tumor growth,
invasion, and metastasis. Specifically, human papillomavirus
(HPV) infection has been shown to be the most important
factor in cervical carcinogenesis: the transformation from
normal cervical epithelium to cervical cancer tissue is most
likely caused by HPVs, which are episomal, double-stranded
DNA viruses that induce epithelial lesions. The oncogenic
potential of high-risk HPV is mostly attributed to the prod-
ucts of three early genes: E5, E6, and E7. E6 and E7 exert their
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Table 1: Characteristics of the clinical cervical tissue samples.
Related
experiment Group Sample type No. Sample HPV genotype∗
Bethesda system&
FIGO stage (N)
Hybridization
HPV16-negative
normal (NN) cervix FFPE 3 Not detected -
HPV16-negative
cervical carcinoma
(NC)
FFPE 3 Not detected CIN II (1), CIN III (2)
Hybridization &
1st qPCR
HPV16-positive
normal (PN) cervix FFPE
1 16 -
2 16 & other -
HPV16-positive
cervical carcinoma
(PC)
FFPE 3 16 CIN III (1), IA1 (2)
2nd qPCR
HPV16-positive
normal (PN) cervix FFPE
2 16 -
2 16 & other -
HPV16-positive
cervical carcinoma
(PC)
FFPE
8 16 IA1 (1), 1B1 (1), IB2 (1),IIA (1), IIB (4)
2 16 & other IA1 (1), 1B1 (1)
Frozen
9 16 IB2 (5), IIA (2), IIB(1), III (1)
3 16 & 18 1B1 (1), IB2 (1), IIA (1)
3 16 & other IB2 (2), IIA (1)
∗HPV genotyping resulted in four categories: not detected, only HPV16 detected (16), co-infected with HPV16 and HPV18 (16 & 18), and co-infected with
HPV16 and high-risk viruses other than HPV16 and HPV18 (16 & other).
Abbreviations: CIN, cervical intraepithelial neoplasia; FFPE, formalin-fixed paraffin-embedded; FIGO, international federation of gynecology and obstetrics;
HPV, human papilloma virus; qPCR, quantitative PCR.
oncogenic effect by destabilizing and degrading retinoblas-
toma protein (pRB) and p53 [1–6], while E5 is thought to play
a role during the early steps of transformation in the basal
layers of the epithelium and enhance the oncogenic effect of
E6 and E7 [7, 8].
Almost all cervical cancers are associated with HPV;
however, the majority of women infected with this virus
do not develop cervical cancer. Therefore, to detect cervical
cancer in high-risk HPV-infected patients, tumor markers
that reflect the virus-induced cancerous changes are needed.
The importance of epigenetic regulatory mechanisms has
become evident in the last decade, and the epigenetic dysreg-
ulation of oncogenes and tumor suppressors is the focus of
active research.MicroRNAs (miRNAs) function as regulators
of different cell processes, such as apoptosis, cell cycle
progression, metastasis, and chemo- and radio-resistance [9,
10]. However, the interaction between viral factors, such as
early oncoproteins, and host factors, such as dysregulated
miRNA expression, during cervical carcinogenesis is still
poorly understood [11–13].
In this study, we aimed to identify potential miRNAs that
may serve as tumormarkers for the early detection of cervical
cancer in high-risk HPV-positive patients. Additionally, we
investigated the association between high-risk HPV onco-
proteins and the dysregulation of miRNAs in cervical cancer
cells.
2. Materials and Methods
2.1. Study Samples and Nucleic Acid Extraction. This study
comprised 41 cervical tissue samples. We obtained 26
formalin-fixed paraffin-embedded (FFPE) and 15 frozen cer-
vical tissues samples from the Korea Gynecologic Cancer
Bank, Yonsei University College of Medicine, Seoul, Republic
of Korea. We divided the collected samples into three control
groups (HPV-negative normal tissues [NN], HPV-negative
cancer tissue [NC], and HPV16-positive normal tissue [PN])
and one experimental group (HPV16-positive cancer tissue
[PC]). Detailed information about these samples is reported
inTable 1. All cancer sampleswere squamous cell carcinomas,
which comprise about 80% of all cervical cancers. HPV
infection was confirmed using the Abbott RealTime High-
Risk HPV PCR assay kit (Abbott Molecular, Abbott Park, IL,
USA).
Total RNA was extracted from the frozen tissues using
the Labozol reagent (CosmoGenetech, Seoul, South Korea)
and from the FFPE tissues using the miRNeasy FFPE kit
(Qiagen, Valencia, CA, USA). RNA was quantitated using
a Nanodrop2000c spectrometer (Thermo Scientific, Wilm-
ington, DE, USA) and DS-11 (DeNovix, Wilmington, DE,
USA) spectrophotometers, and the quantitation and quality
of the isolated samples were confirmed using the Agilent 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
2.2. miRNA Screening Using the Hybridization Method. RNA
was extracted from 12 FFPE cervical tissue samples con-
sisting of three samples from each of the NN, PN, NC,
and PC groups. Total RNA from each sample (100 ng) was
prepared as instructed in the nCounter miRNA Expression
Assay (NanoString Technologies, Seattle, WA, USA) user
manual. Mature miRNAs were ligated to a species-specific
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tag sequence (miRtag). After enzymatic purification of non-
ligated miRtags, the prepared samples were hybridized using
the nCounter Human v3 miRNA Expression Assay CodeSet
containing 800 human miRNA hybridization probes. After
hybridization, the excess probes were removed by two-step
magnetic bead-based purification on the nCounter Prep
station. Specific target molecules were quantified using the
nCounter Digital Analyzer, by counting individual fluores-
cent barcodes and assessing target molecule levels. For each
sample, a scan encompassing 280 fields of view was per-
formed. The data were collected using the nCounter Digital
Analyzer after taking images of the immobilized fluorescent
reporters in the sample cartridge (NanoString Technologies).
2.3. Quantitative Polymerase Chain Reaction (qPCR) Analyses
of Clinical Samples. To investigate the changes in miRNA
expression levels, we performed qPCR analysis of the samples
obtained with the hybridization method. Additionally, we
validated eight miRNAs in the 29 clinical tissue samples
that had not been used in the miRNA hybridization (4 PN
and 25 PC). Reverse transcription was performed using the
miScript II RT Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. qPCR was performed on the
StepOnePlus Real-Time PCR System (Applied Biosystems,
Carlsbad, CA, USA) using the 2× QuantiTect SYBR Green
PCR Master Mix (Qiagen). Thermal cycling conditions were
as follows: 95∘C for 15 min, followed by 40 cycles of 94∘C for
15 s and 55∘C for 30 s, and 70∘C for 30 s.The data was analyzed
using the StepOne software v2.2.2 (Applied Biosystems). All
qPCR reactions were run in triplicate, and gene expression
levels of each miRNA were normalized to the levels of the
endogenous control small RNAU6, using the 2-ΔΔCt method.
2.4. HPV16 E5/E6/E7 Silencing in Cancer Cells In Vitro. We
investigated the effect of HPV16 oncoproteins on human
miRNA expression using two human cervical cancer cell
lines: HPV16-positive CaSki cells (ATCC CRL-1550; Amer-
ican Type Culture Collection [ATCC], Manassas, VA, USA)
and SiHa cells (ATCC HTB-35; ATCC). Cervical cancer cells
were cultured in RPMI-1640 medium (Gibco BRL, Grand
Island, New York, USA), supplemented with 10% fetal bovine
serum (GibcoBRL) and 1%penicillin/streptomycin under 5%
CO
2
at 37∘C. To investigate the role of HPV16 E5, E6, and E7
on the expression of miRNAs during cervical carcinogenesis,
we silenced the E5 gene using small hairpin RNA (shRNA)
overexpressed by lentiviral vectors and the bicistronic E6/E7
genes using small interfering RNA (siRNA) in cervical cancer
cells, as previously reported [14, 15]. Scrambled shRNA or
siRNA sequences were used as a negative control.
Cells were transfected/infected in 12-well plates and
collected 0, 24, 48, and 72 h after. Total RNA was extracted
with the TRIzol reagent (Invitrogen, Carlsbad, CA, USA).
The efficiency of knockdown was determined by measuring
the expression levels of HPV16 E5/E6/E7 mRNA three times
by qPCR at 72 h after transfection/infection. The levels of
miRNA expression were also determined using qPCR at
the indicated time-points. Primer sets described previously
[14] were used to amplify each miRNA. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as an inter-
nal control.
2.5. Data Analysis. For miRNA profiling, the reporter counts
were collected using the nSolver software v3.0.22 (NanoString
Technologies). miRNA profiling data were normalized by
positive reaction controls to a panel of five housekeeping
genes (actin B [ACTB], 𝛽2 microglobulin [B2M], GAPDH,
and ribosomal proteins [RP] L19 and L10) and to miRNA-
23a and miRNA-191 [16]. The R software v.3.1.1 was used for
analysis and graphics construction [17]. Differences between
the samples were considered significant at a fold change ≥ 2
and P ≤ 0.01. For qPCR analysis, all data were expressed as the
mean± standard deviation. Statistical differences between the
groupswere assessed using Student’s two-tailed t-test.P< 0.05
was considered to indicate a statistically significant difference.
3. Results
3.1. miRNA Proﬁling in Cervical Tissues. The expression
profile of 800 human miRNAs in the PC and PN groups was
analyzed using the hybridization method. We identified 99
differentially expressed miRNAs (fold change ≥ 2 and P ≤
0.01) between the two groups. Among these, eight miRNAs
had significantly different expression in the PC group com-
pared with pooled control group (combined NN, NC, and
PN groups). Six miRNAs were upregulated and two were
downregulated in the PC group compared to the control
group. Figure 1 shows the heat map indicating these eight
differentially expressed miRNAs.
3.2. Diﬀerentially Expressed miRNAs in Cervical Cancer. To
verify the results of the miRNA expression profiles, we
reevaluated the expression of the eight identified miRNAs,
by qPCR. We found that miR-148a-3p, miR-190a-5p, miR-
199b-5p, and miR-655-3p levels were significantly decreased
in the PC group compared to the PN group (respective 0.22-
fold, 0.11-fold, 0.11-fold, and 0.11-fold), while the levels of
other miRNAs did not significantly differ between the two
groups (Figure 2(a)). Notably, only the results regarding miR-
655-3p expression were consistent with those obtained using
the hybridization method. Analysis of additional clinical
tissue samples showed that miR-190a-5p, miR-199b-5p, and
miR-655-3p expression was significantly decreased in the PC
group compared with the PN (control) group (respective
0.32-fold, 0.12-fold, and 0.18-fold; Figure 2(b)).
Four miRNAs, whose expression was significantly differ-
ent in the PC and PN groups, were analyzed according to
the International Federation of Gynecology and Obstetrics
(FIGO) staging system classification of the tissue samples
(Figure 3 & Table 2). We found that the expression of these
miRNAs in the PC group significantly decreased in almost all
FIGO stages compared to the PN group, with the exception
of miR-148a-3p expression in the IB group, characterized
by clinically visible lesions confined to the cervix (stromal
invasion > 5.0mm in depth or >7.0mm in horizontal spread).
The relative expression folds for each FIGO stage compared
to the PN group are shown in detail in Table 2. Furthermore,
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Figure 1: Differential miRNA expression in cervical tissues. Heat map indicating the eight differentially expressed miRNAs in cervical
cancer tissues. NN, HPV16-negative normal; NC, HPV16-negative carcinoma; PN, HPV16-positive normal; PC, HPV16-positive carcinoma.
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Figure 2:Relative expression of selectedmiRNAs in cervical tissues. (a) Expression of the indicatedmiRNA assessedwith the hybridization
method (3 PN vs. 3 PC). (b) Expression of the indicated miRNA assessed with the hybridization method in additional samples (4 PN vs. 25
PC). PN, HPV16-positive normal; PC, HPV16-positive carcinoma. ∗, P< 0.05; ∗∗, P< 0.001; ∗ ∗ ∗, P< 0.0001.
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Figure 3:Relative expression of selectedmiRNA according to the International Federation of Gynecology andObstetrics (FIGO) stages
of the samples.TheHPV16-positive cancer (PC) group (IA [n = 4], 1B [n = 12], IIA [n = 5], IIB+III [n = 6]) were compared with the HPV16-
positive normal group (PN; n = 5). ∗, P < 0.05; ∗∗, P < 0.001; ∗ ∗ ∗, P < 0.0001.
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Figure 4: E5,E6, and E7 expression levels afterRNA interference.
Relative expression of E5, E6, and E7 mRNA 72 h after shRNA or
siRNA-mediated silencing in CaSki and SiHa cells. GAPDH was
used for normalization. ∗, P < 0.05; ∗∗, P < 0.01.
the expression levels of these miRNAwere shown to decrease
gradually as the disease progressed.
3.3. HPV16 E5/E6/E7 Eﬀect on Host miRNA Expression.
HPV16 E5, E6, and E7 silencing reduced the expression of
these genes by 0.53-fold, 0.85-fold, and 0.49-fold in CaSki
cells and by 0.74-fold, 0.62-fold, and 0.50-fold in SiHa
cells, compared to control samples, overexpressing scramble
shRNAor siRNA (Figure 4).We then determined the relative
expression levels of the selected four miRNAs in Ca Ski
and SiHa cervical cancer cells and compared them with
the miRNA levels in control samples, at the indicated time
points after transfection/infection. miR-148a-3p expression
significantly increased in both cell lines 72 h after gene
silencing, especially in the E6/E7 knockdown group, while
miR-199b-5p showed a variable expression pattern and its
levels were significantly increased only in SiHa cells 72 h
after E6/E7 silencing. miR-190a-5p expression significantly
increased in CaSki cells 72 h after E5 silencing and in
SiHa cells72 h after E6/E7 silencing. However, no significant
changes in miR-655-3p levels were observed (Figure 5).
4. Discussion
The correlation between changes in miRNA expression and
cervical cancer development was originally described in 2009
[18]. The authors of the study showed that the expression of
miR-21 promotes HeLa cell proliferation, while its inhibition
suppresses cell proliferation by inducing the overexpression
of the tumor-suppressor gene programmed cell death 4
(PDCD4), a programmed cell death protein. miR-21 was
subsequently demonstrated to be an important oncomir,
overexpressed in a wide variety of cancers, including cervical
cancer [19].
Several miRNAs, such as miR-34a, miR-886-5p, miR-143,
miR-203, and miR-155, have been shown to have differential
expression in cervical cancer and normal samples [20–24].
Therefore, miRNAs have been studied as potential diagnostic
biomarkers in cancer development and progression and as
therapeutic targets for cervical cancer treatment [25–27]. In
2014, Sharma et al. [28] reviewed 246 differentially expressed
miRNAs involved in cervical cancer progression.
However, to date, no miRNAs are used practically as
markers for the diagnosis of cervical cancer. One of the
possible reasons is the lack of consistency in the research
data, which makes it difficult to determine the clinical
value of the identified miRNA. Inconsistency in miRNA
expression levels in cervical carcinogenesis may be attributed
to patient-intrinsic variation, time and temperature changes
during sample collection, processing, contamination by cells
and blood components, RNA extraction method used, nor-
malization, and storage time and conditions [29]. Another
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Figure 5: Effects of E5 and E6/E7 silencing on the expression of selected miRNAs.The expression of the indicated miRNA was assessed
by qPCR in CaSki and SiHa cells at different time points after E5 and E6/E7 silencing. GAPDH was used for normalization. ∗, P < 0.05 and
∗∗, P < 0.01, compared with the scramble control samples.
important issue is the necessity to optimize the technology to
applymicroRNA gene expression analysis to clinical practice;
specifically, for high sensitivity, high specificity, and technical
reproducibility, low cost and proper outputs are required.
In this study, we focused on the most prevalent HPV
type (HPV16) and cervical squamous cell carcinoma (FIGO
stages IB1 ∼ III). We screened 800 human miRNAs, to
identify potential novel biomarkers and investigated the
effects of HPV16 oncoproteins on selected miRNAs. We ana-
lyzed the results obtained in HPV16-positive cancer samples
and compared them to those from HPV16-positive healthy
individuals, to identify early diagnostic markers for cancer
development in high-risk HPV-infected patients. Our study
has several limitations, such as the difficulty of relying on
the results obtained using banked tissue samples, due to
the inability of controlling preanalytical factors. Different
conditions associated with sample processing, storage, RNA
extraction, and collection time, all important determinants of
miRNA stability, were used to collect the samples, from May
2012 to March 2017. Additionally, the samples initially tested
for screening included high-grade squamous intraepithelial
lesions, a noninvasive cancer.
We identified eight miRNAs as putative biomarkers in
HPV16-positive cervical cancer tissues: miR-9-5p, miR-136-
5p, miR-148a-3p, miR-190a-5p, miR-199b-5p, and miR-382-
5p (upregulated) and miR-597-5p and miR-655-3p (down-
regulated). It has previously been reported that miR-148a
expression is altered during cancer development and may
serve as a specific marker for HPV-induced malignancy [30,
31]. miR-136 has been shown to be downregulated inminimal
deviation adenocarcinomas of the uterine cervix, while miR-
9 is upregulated in cervical cancers, and its upregulation is
8 BioMed Research International
associated with lymph nodemetastases and vascular invasion
[32, 33]. miR-199b-5p has been reported to be downregulated
in squamous cell carcinoma and is associated with poor
prognosis [34].
Among the eight identified miRNAs, miR-148a-3p, miR-
190a-5p, miR-199b-5p, and miR-655 expression was shown
to be significantly suppressed in the PC group by qPCR.
The results for miR-148a, miR-190a, and miR-199b obtained
with the hybridization and qPCR methods were discordant.
One possible reason for the discrepancy is that the reference
genes used to normalize the data were different in the two
methods. All reference genes were selected according to
previously published studies [14, 16]. Notably, the difference
in the expression levels might depend on the instability of
specific miRNAs. Specifically, the stability of nucleic acids
extracted from FFPE samples may be reduced. While we
verified the quality of extracted RNA, it should be noted
that we evaluated the quality of total isolated RNA, not that
of specific miRNAs. Finally, the small number of samples
used for screening increased the chances for nonsignificant
results.
On this note, Mestdag et al. [35] have compared 12
available platforms formiRNA expression analysis and found
that the concordance ofmiRNA expression was less than 70%
between hybridization and qPCR. Particularly, the average
validation rate of miRNA levels when using any platform
combination was only 54.6% (95% confidential interval,
52.5–56.7%). Notably, the silencing efficiency was about
50–60% for E5 and E7 in CaSki cells and E6 and E7 in
SiHa cells. This was due to the difference in HPV16 copy
number per cell and because of cell characteristics (such as
race and histologic type). The silencing of HPV16 E5 and
E6/E7 was shown to inhibit miR-148a-3p expression in both
the cell lines, while the silencing of HPV16 E6/E7 in SiHa
cells increased miR-199b-5p and miR-190a-5p expression
levels.
5. Conclusion
In this study, we found that three HPV16 oncoproteins
were associated with the downregulation of miR-148a-3p
expression, while HPV16 E6/E7 led to the downregulation
of miR-199b-5p and miR-190a-5p in cervical carcinoma. Our
results suggest that miR-148a, miR-199b, and miR-190a may
be novel biomarkers for cervical carcinogenesis after HPV16
infection.
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